The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression

Chunbo He, Dagan Mao, Guohua Hua, Xiangmin Lv, Xingcheng Chen, Peter C Angeletti, Jixin Dong, Steven W Remmenga, Kerry J Rodabaugh, Jin Zhou, Paul F. Lambert, Peixin Yang, John S Davis, Cheng Wang

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

The Hippo signaling pathway controls organ size and tumorigenesis through a kinase cascade that inactivates Yes-associated protein (YAP). Here, we show that YAP plays a central role in controlling the progression of cervical cancer. Our results suggest that YAP expression is associated with a poor prognosis for cervical cancer. TGF-α and amphiregulin (AREG), via EGFR, inhibit the Hippo signaling pathway and activate YAP to induce cervical cancer cell proliferation and migration. Activated YAP allows for up-regulation of TGF-α, AREG, and EGFR, forming a positive signaling loop to drive cervical cancer cell proliferation. HPV E6 protein, a major etiological molecule of cervical cancer, maintains high YAP protein levels in cervical cancer cells by preventing proteasome-dependent YAP degradation to drive cervical cancer cell proliferation. Results from human cervical cancer genomic databases and an accepted transgenic mouse model strongly support the clinical relevance of the discovered feed-forward signaling loop. Our study indicates that combined targeting of the Hippo and the ERBB signaling pathways represents a novel therapeutic strategy for prevention and treatment of cervical cancer.

Original languageEnglish (US)
Pages (from-to)1426-1449
Number of pages24
JournalEMBO Molecular Medicine
Volume7
Issue number11
DOIs
StatePublished - Nov 2015

Fingerprint

Oncogene Proteins
Uterine Cervical Neoplasms
Proteins
Cell Proliferation
Organ Size
Proteasome Endopeptidase Complex
Transgenic Mice
Proteolysis
Cell Movement
Carcinogenesis
Phosphotransferases
Up-Regulation
Databases

Keywords

  • Cervical cancer
  • EGFR
  • HPV
  • Hippo
  • YAP

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. / He, Chunbo; Mao, Dagan; Hua, Guohua; Lv, Xiangmin; Chen, Xingcheng; Angeletti, Peter C; Dong, Jixin; Remmenga, Steven W; Rodabaugh, Kerry J; Zhou, Jin; Lambert, Paul F.; Yang, Peixin; Davis, John S; Wang, Cheng.

In: EMBO Molecular Medicine, Vol. 7, No. 11, 11.2015, p. 1426-1449.

Research output: Contribution to journalArticle

He, Chunbo ; Mao, Dagan ; Hua, Guohua ; Lv, Xiangmin ; Chen, Xingcheng ; Angeletti, Peter C ; Dong, Jixin ; Remmenga, Steven W ; Rodabaugh, Kerry J ; Zhou, Jin ; Lambert, Paul F. ; Yang, Peixin ; Davis, John S ; Wang, Cheng. / The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. In: EMBO Molecular Medicine. 2015 ; Vol. 7, No. 11. pp. 1426-1449.
@article{e62321ad408847bdb5b1b69f6aa7f46e,
title = "The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression",
abstract = "The Hippo signaling pathway controls organ size and tumorigenesis through a kinase cascade that inactivates Yes-associated protein (YAP). Here, we show that YAP plays a central role in controlling the progression of cervical cancer. Our results suggest that YAP expression is associated with a poor prognosis for cervical cancer. TGF-α and amphiregulin (AREG), via EGFR, inhibit the Hippo signaling pathway and activate YAP to induce cervical cancer cell proliferation and migration. Activated YAP allows for up-regulation of TGF-α, AREG, and EGFR, forming a positive signaling loop to drive cervical cancer cell proliferation. HPV E6 protein, a major etiological molecule of cervical cancer, maintains high YAP protein levels in cervical cancer cells by preventing proteasome-dependent YAP degradation to drive cervical cancer cell proliferation. Results from human cervical cancer genomic databases and an accepted transgenic mouse model strongly support the clinical relevance of the discovered feed-forward signaling loop. Our study indicates that combined targeting of the Hippo and the ERBB signaling pathways represents a novel therapeutic strategy for prevention and treatment of cervical cancer.",
keywords = "Cervical cancer, EGFR, HPV, Hippo, YAP",
author = "Chunbo He and Dagan Mao and Guohua Hua and Xiangmin Lv and Xingcheng Chen and Angeletti, {Peter C} and Jixin Dong and Remmenga, {Steven W} and Rodabaugh, {Kerry J} and Jin Zhou and Lambert, {Paul F.} and Peixin Yang and Davis, {John S} and Cheng Wang",
year = "2015",
month = "11",
doi = "10.15252/emmm.201404976",
language = "English (US)",
volume = "7",
pages = "1426--1449",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression

AU - He, Chunbo

AU - Mao, Dagan

AU - Hua, Guohua

AU - Lv, Xiangmin

AU - Chen, Xingcheng

AU - Angeletti, Peter C

AU - Dong, Jixin

AU - Remmenga, Steven W

AU - Rodabaugh, Kerry J

AU - Zhou, Jin

AU - Lambert, Paul F.

AU - Yang, Peixin

AU - Davis, John S

AU - Wang, Cheng

PY - 2015/11

Y1 - 2015/11

N2 - The Hippo signaling pathway controls organ size and tumorigenesis through a kinase cascade that inactivates Yes-associated protein (YAP). Here, we show that YAP plays a central role in controlling the progression of cervical cancer. Our results suggest that YAP expression is associated with a poor prognosis for cervical cancer. TGF-α and amphiregulin (AREG), via EGFR, inhibit the Hippo signaling pathway and activate YAP to induce cervical cancer cell proliferation and migration. Activated YAP allows for up-regulation of TGF-α, AREG, and EGFR, forming a positive signaling loop to drive cervical cancer cell proliferation. HPV E6 protein, a major etiological molecule of cervical cancer, maintains high YAP protein levels in cervical cancer cells by preventing proteasome-dependent YAP degradation to drive cervical cancer cell proliferation. Results from human cervical cancer genomic databases and an accepted transgenic mouse model strongly support the clinical relevance of the discovered feed-forward signaling loop. Our study indicates that combined targeting of the Hippo and the ERBB signaling pathways represents a novel therapeutic strategy for prevention and treatment of cervical cancer.

AB - The Hippo signaling pathway controls organ size and tumorigenesis through a kinase cascade that inactivates Yes-associated protein (YAP). Here, we show that YAP plays a central role in controlling the progression of cervical cancer. Our results suggest that YAP expression is associated with a poor prognosis for cervical cancer. TGF-α and amphiregulin (AREG), via EGFR, inhibit the Hippo signaling pathway and activate YAP to induce cervical cancer cell proliferation and migration. Activated YAP allows for up-regulation of TGF-α, AREG, and EGFR, forming a positive signaling loop to drive cervical cancer cell proliferation. HPV E6 protein, a major etiological molecule of cervical cancer, maintains high YAP protein levels in cervical cancer cells by preventing proteasome-dependent YAP degradation to drive cervical cancer cell proliferation. Results from human cervical cancer genomic databases and an accepted transgenic mouse model strongly support the clinical relevance of the discovered feed-forward signaling loop. Our study indicates that combined targeting of the Hippo and the ERBB signaling pathways represents a novel therapeutic strategy for prevention and treatment of cervical cancer.

KW - Cervical cancer

KW - EGFR

KW - HPV

KW - Hippo

KW - YAP

UR - http://www.scopus.com/inward/record.url?scp=84946472055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946472055&partnerID=8YFLogxK

U2 - 10.15252/emmm.201404976

DO - 10.15252/emmm.201404976

M3 - Article

C2 - 26417066

AN - SCOPUS:84946472055

VL - 7

SP - 1426

EP - 1449

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 11

ER -